BioAge Labs (BIOA) Stock Price, News & Analysis

Company Overview

BioAge Labs, Inc. (NASDAQ:BIOA) is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. Its research uses human longevity data and proprietary computational biology tools to identify pathways associated with aging-related diseases and to develop potential therapies aimed at extending healthy lifespan and improving physical function.

The company’s lead investigational program is azelaprag, also known as BGE-105, an oral small-molecule apelin receptor agonist being studied for its potential to preserve muscle mass and improve physical performance in older adults. BioAge is also evaluating its broader pipeline in areas such as obesity, metabolic disease, muscle health and immune function, although its programs remain in clinical development and have not been approved for commercial use.

BioAge was founded in 2015 and is headquartered in Richmond, California. The company’s operations are centered on research, drug discovery and clinical development, with studies conducted in collaboration with clinical and research organizations. Kristen Fortney, Ph.D., is the company’s co-founder, president and chief executive officer.

Key Stats

• Today's Range: $7.68 to $8.49
• 50-Day Range: $7.75 to $24.85
• 52-Week Range: $4.94 to $25.95
• Volume: 618,445 shs
• Average Volume: 630,065 shs
• Market Capitalization: $362.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.57
• Consensus Rating: Moderate Buy

BioAge Labs Stock Analysis - MarketRank™

BioAge Labs scored higher than 37% of companies evaluated by MarketBeat, and ranked 670th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioAge Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

BioAge Labs has a consensus price target of $36.57, representing about 363.5% upside from its current price of $7.89.

Amount of Analyst Coverage

BioAge Labs has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioAge Labs are expected to grow in the coming year, from ($2.45) to ($2.28) per share.

Price to Book Value per Share Ratio

BioAge Labs has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.19% of the float of BioAge Labs has been sold short.

Short Interest Ratio / Days to Cover

BioAge Labs has a short interest ratio ("days to cover") of 4.72.

Change versus previous month

Short interest in BioAge Labs has recently increased by 22.78%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioAge Labs does not currently pay a dividend.

Dividend Growth

BioAge Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for BioAge Labs this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for BIOA on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added BioAge Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioAge Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.55% of the stock of BioAge Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

BioAge Labs has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:BIOA
• Previous Symbol: NYSE:BIOA
• CIK: 1709941
• Web: bioagelabs.com
• Phone: (510) 806-1445
• Fax: N/A
• Employees: 62
• Year Founded: 2015

Price Target and Rating

• Average Price Target for BioAge Labs: $36.57
• High Price Target: $60.00
• Low Price Target: $21.00
• Potential Upside/Downside: +363.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$80.61 million
• Net Margins: -912.26%
• Pretax Margin: -912.26%
• Return on Equity: -28.99%
• Return on Assets: -27.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.19
• Quick Ratio: 17.19

Sales & Book Value

• Annual Sales: $8.99 million
• Price / Sales: 40.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.59 per share
• Price / Book: 1.04

Miscellaneous

• Outstanding Shares: 45,900,000
• Free Float: 37,842,000
• Market Cap: $362.15 million
• Optionable: N/A
• Beta: 0.94